|
Gene: SORCS2 |
Gene summary for SORCS2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SORCS2 | Gene ID | 57537 |
Gene name | sortilin related VPS10 domain containing receptor 2 | |
Gene Alias | SORCS2 | |
Cytomap | 4p16.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q96PQ0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57537 | SORCS2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.65e-21 | 7.48e-01 | 0.0155 |
57537 | SORCS2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.41e-14 | 6.16e-01 | -0.1808 |
57537 | SORCS2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.18e-05 | 1.19e+00 | 0.0216 |
57537 | SORCS2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.59e-26 | 1.40e+00 | -0.0811 |
57537 | SORCS2 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.57e-06 | 4.17e-01 | -0.1088 |
57537 | SORCS2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.09e-40 | 1.46e+00 | -0.1954 |
57537 | SORCS2 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.19e-11 | 1.09e+00 | -0.2602 |
57537 | SORCS2 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.33e-08 | 7.99e-01 | -0.2196 |
57537 | SORCS2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.52e-17 | 1.20e+00 | -0.1207 |
57537 | SORCS2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.74e-19 | 8.59e-01 | -0.1526 |
57537 | SORCS2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.53e-29 | 7.26e-01 | -0.1464 |
57537 | SORCS2 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.78e-35 | 1.08e+00 | -0.1001 |
57537 | SORCS2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.45e-23 | 9.78e-01 | -0.059 |
57537 | SORCS2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.05e-16 | 1.31e+00 | -0.1706 |
57537 | SORCS2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.11e-05 | 3.03e-01 | -0.2061 |
57537 | SORCS2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 7.38e-13 | 1.48e+00 | -0.1462 |
57537 | SORCS2 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.02e-09 | 6.86e-01 | -0.0842 |
57537 | SORCS2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.97e-02 | 4.19e-01 | -0.00410000000000005 |
57537 | SORCS2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.55e-03 | 1.81e-01 | 0.096 |
57537 | SORCS2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.98e-03 | 4.12e-01 | 0.0131 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0050804 | Colorectum | CRC | modulation of chemical synaptic transmission | 70/2078 | 439/18723 | 1.15e-03 | 1.33e-02 | 70 |
GO:0099177 | Colorectum | CRC | regulation of trans-synaptic signaling | 70/2078 | 440/18723 | 1.23e-03 | 1.38e-02 | 70 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SORCS2 | SNV | Missense_Mutation | rs774161295 | c.1892G>T | p.Arg631Leu | p.R631L | Q96PQ0 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
SORCS2 | SNV | Missense_Mutation | novel | c.2886N>A | p.Met962Ile | p.M962I | Q96PQ0 | protein_coding | tolerated(0.3) | benign(0) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SORCS2 | SNV | Missense_Mutation | rs778161381 | c.3375C>A | p.Ser1125Arg | p.S1125R | Q96PQ0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SORCS2 | SNV | Missense_Mutation | rs746661005 | c.2419G>A | p.Glu807Lys | p.E807K | Q96PQ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.616) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
SORCS2 | deletion | Frame_Shift_Del | novel | c.3471delN | p.Val1158Ter | p.V1158* | Q96PQ0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SORCS2 | SNV | Missense_Mutation | novel | c.1255C>T | p.Pro419Ser | p.P419S | Q96PQ0 | protein_coding | tolerated(0.73) | benign(0.021) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SORCS2 | SNV | Missense_Mutation | novel | c.1735A>G | p.Thr579Ala | p.T579A | Q96PQ0 | protein_coding | tolerated(0.09) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SORCS2 | SNV | Missense_Mutation | rs746615942 | c.2804N>A | p.Arg935His | p.R935H | Q96PQ0 | protein_coding | tolerated(0.15) | possibly_damaging(0.702) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SORCS2 | SNV | Missense_Mutation | c.1115N>A | p.Arg372Gln | p.R372Q | Q96PQ0 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SORCS2 | SNV | Missense_Mutation | c.2058N>T | p.Lys686Asn | p.K686N | Q96PQ0 | protein_coding | tolerated(0.32) | benign(0.441) | TCGA-FU-A770-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
57537 | SORCS2 | NA | atazanavir | ATAZANAVIR | 31562781 |
Page: 1 |